TY  - RPRT
TI  - Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting.
AU  - G Curigliano
AU  - M De Laurentiis
AU  - N Harbeck
AU  - S Kuemmel
AU  - J Á García-Sáenz
AU  - R Sanchez Bayona
AU  - D Rea
AU  - A Okines
AU  - B Pistilli
AU  - E Sears
AU  - J Maitland
AU  - S Kloss
AU  - T Wasserman
AU  - M Ignatiadis
PY  - 2026
DO  - 10.1016/j.esmoop.2026.108535
UR  - https://pubmed.ncbi.nlm.nih.gov/42735454/
ID  - 42735454
ER  -